- Conditions
- Sinus Node Dysfunction, Heart Block AV, LBBB, Heart Failure, Systolic
- Interventions
- Conventional fluoroscopy guided Conduction System Pacing(CSP), Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)
- Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 2,391
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Orthopedic Surgery of Lower Extremity
- Interventions
- 0.2% ropivacaine, saline
- Device · Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Carotid Artery Stenosis
- Interventions
- GORE Flow Reversal System (GFRS)
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Cleveland, Ohio
- Conditions
- Aortic Valve Stenosis
- Interventions
- TAVR with CENTERA THV
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- Not listed
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Stanford, California • Loveland, Colorado + 19 more
- Conditions
- Procedural Anxiety, Procedural Pain
- Interventions
- Remimazolam 20 MG [Byfavo]
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Pain, Amputation
- Interventions
- 10 mL 2% lidocaine, 10 mL preservative free saline
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Symptomatic Severe Aortic Stenosis
- Interventions
- TAVR
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 1,074 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 51
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 44 more
- Conditions
- Local Anesthetic Complication, Local Anesthetic Drug Adverse Reaction
- Interventions
- Not listed
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Nephrectomy
- Interventions
- Transverses Abdominis Plane (TAP) block, Quadratus Lumborum (QL) block, Surgeon Infiltration using Exparel
- Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Healthy Volunteers
- Interventions
- SKY0402
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Acute Myocardial Infarction (AMI), Coronary Occlusion, Acute Coronary Syndrome
- Interventions
- Guardian System
- Device
- Lead sponsor
- Angel Medical Systems
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 85 more
- Conditions
- Nasal Congestion
- Interventions
- Carbon Dioxide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Chandler, Arizona • Pinellas Park, Florida • Paramus, New Jersey + 1 more
- Conditions
- Nasal Obstruction
- Interventions
- Mechanical nasal dilator
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Small Bowel Obstruction, Ileus
- Interventions
- No clamp trial, Clamp trial
- Other
- Lead sponsor
- University of Illinois College of Medicine at Peoria
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Peoria, Illinois
- Conditions
- Cardiomyopathies, Heart Failure, Non-left Bundle Branch Block, Cardiac Resynchronization Therapy
- Interventions
- CRT-D implantation
- Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Left Atrial Appendage Occlusion
- Interventions
- intra-procedural intracardiac echocardiography (ICE) probe
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Rochester, Minnesota
- Conditions
- Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
- Interventions
- Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
- Combination Product
- Lead sponsor
- MediBeacon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Sleep Disorders, Congestion, Nasal
- Interventions
- Prototype Nasal Dilator, Marketed Nasal Strip, Placebo Nasal Strip
- Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Paramus, New Jersey • Bethlehem, Pennsylvania
- Conditions
- Central Retinal Artery Occlusion
- Interventions
- KUS121 high dose, KUS121 low dose, Sham procedure
- Drug
- Lead sponsor
- Kyoto Drug Discovery and Development Co., Ltd.
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- Encino, California • Huntington Beach, California • Oakland, California + 8 more
- Conditions
- Pain, Postoperative
- Interventions
- Interscalene block with the addition of buprenorphine, clonidine, dexamethasone, Interscalene block with buprenorphine alone
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Cystectomy
- Interventions
- epidural bupivacaine 0.05%, Liposomal bupivacaine, bupivacaine 0.125%, bupivacaine 0.5%, /hydromorphone 0.05mg/ml, injectable saline
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Postoperative Pain
- Interventions
- Placebo, EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more
- Conditions
- Renal Failure Congenital, Congenital Renal Anomaly Nos, Renal Agenesis and Dysgenesis, Lower Urinary Tract Obstructive Syndrome
- Interventions
- Lactated Ringers Solution for Injection
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug, Placebo EP-101, Tiotropium bromide via (Spiriva® Handihaler®), Ipratropium bromide Inhalation Solution via Handihaler® DPI, EP-101 via nebulizer (eFlow®) 200 ug
- Drug
- Lead sponsor
- Sunovion Respiratory Development Inc.
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more